|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.11 USD | -1.70% |
|
+3.98% | +28.02% |
| 07-07 | RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating | MT |
| 07-02 | Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 14.1B | |||||
| 56.71B | |||||
| 51.3B | |||||
| 25.26B | - | ||||
| 23.65B | - | ||||
| 18.69B |
- Stock Market
- Stocks
- EXEL Stock
- Charts Exelixis, Inc.
- Sector Chart
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
